Filtered By:
Condition: Heart Failure
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 331 results found since Jan 2013.

Assessing Optimal Blood Pressure in Patients with Asymptomatic Aortic Valve Stenosis: The SEAS Study.
CONCLUSIONS: -Optimal BP seems to be systolic 130-139 mmHg and diastolic 70-90 mmHg in these patients with asymptomatic AS and no manifest atherosclerotic disease or diabetes. Clinical Trial Registration-http://www.clinicaltrials.gov; NCT00092677. PMID: 27486164 [PubMed - as supplied by publisher]
Source: Circulation - August 1, 2016 Category: Cardiology Authors: Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K Tags: Circulation Source Type: research

Protection of cardiac cell-to-cell coupling attenuate myocardial remodeling and proarrhythmia induced by hypertension.
Abstract Gap junction connexin channels are important determinants of myocardial conduction and synchronization that is crucial for coordinated heart function. One of the main risk factors for cardiovascular events that results in heart attack, congestive heart failure, stroke as well as sudden arrhythmic death is hypertension. Mislocalization and/or dysfunction of specific connexin-43 channels due to hypertension-induced myocardial remodeling have been implicated in the occurrence of life-threatening arrhythmias and heart failure in both, humans as well as experimental animals. Recent studies suggest that down-re...
Source: Physiological Research - September 18, 2016 Category: Physiology Authors: Egan Benova T, Szeiffova Bacova B, Viczenczova C, Diez E, Barancik M, Tribulova N Tags: Physiol Res Source Type: research

Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
CONCLUSION: Real-world CVD burden is substantial. Using the observed CVD burden in CPRD and the CTTC relationship, the cost-effectiveness analysis showed that, accounting for uncertainties, the expected value-based price for evolocumab is higher than its current annual cost as long as the payer discount off list price is greater than 20%. PMID: 28097904 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 19, 2017 Category: Health Management Tags: J Med Econ Source Type: research

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
Publication date: Available online 26 January 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Eberhard Standl, Oliver Schnell, Darren K McGuire, Antonio Ceriello, Lars Rydén Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven cardiovascular and renal benefit, the antihyperglycaemic drugs empagliflozin, lira...
Source: The Lancet Diabetes and Endocrinology - January 25, 2017 Category: Endocrinology Source Type: research

Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients with Myocardial Infarction with Non-Obstructive Coronary Artery (MINOCA) Disease.
Conclusions -The results indicate long-term beneficial effects on outcome in patients with MINOCA of treatment with statins and ACEI/ARBs, a trend toward a positive effect of beta-blocker treatment, and a neutral effect of DAPT. Properly powered randomized clinical trials to confirm these results are warranted. PMID: 28179398 [PubMed - as supplied by publisher]
Source: Circulation - February 7, 2017 Category: Cardiology Authors: Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld AM, Gard A, Jernberg T Tags: Circulation Source Type: research

Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry
CONCLUSIONS The presence of diabetes markedly increases the risk of 1-year adverse clinical outcomes in outpatients with CHF independent of multiple common risk factors. More effective and personalized treatment for diabetes should be considered in this particularly high-risk patient population.
Source: Diabetes Care - April 20, 2017 Category: Endocrinology Authors: Dauriz, M.; Targher, G.; Laroche, C.; Temporelli, P. L.; Ferrari, R.; Anker, S.; Coats, A.; Filippatos, G.; Crespo-Leiro, M.; Mebazaa, A.; Piepoli, M. F.; Maggioni, A. P.; Tavazzi, L.; for the ESC-HFA Heart Failure Long-Term Registry Tags: Cardiovascular and Metabolic Risk Source Type: research

Heart attack breakthrough - THIS drug could be more effective than statins
STROKE risk and heart failure could be treated with a new therapy - which could be more effective and have fewer side effects than statins - the widely-prescribed cholesterol-busting drugs.
Source: Daily Express - Health - May 22, 2017 Category: Consumer Health News Source Type: news

Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation
ConclusionPeripheral arterial disease is prevalent in 11% of AF patients and related to various atherosclerotic risk factors. Even if PAD is associated with higher risk of all-cause death on univariate analysis, this risk was significantly lowered and was no longer evident after adjusting for the use of CV prevention drugs.
Source: Europace - December 9, 2016 Category: Cardiology Source Type: research

Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Conclusions -Heretofore unknown effects of torcetrapib were revealed in immune and inflammatory functions. A protein-based risk score predicted harm from torcetrapib within just 3 months. A protein-based risk assessment embedded within a large proteomic survey may prove to be useful in the evaluation of therapies to prevent harm to patients. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique Identifier: NCT00134264. PMID: 28974520 [PubMed - as supplied by publisher]
Source: Circulation - October 3, 2017 Category: Cardiology Authors: Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P Tags: Circulation Source Type: research

Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
CONCLUSION: Post-trial follow-up revealed continued deleterious AF/AFL effects. The amlodipine (ALLHAT) and pravastatin (ALLHAT-LLT) treatment groups showed lower all-cause and non-CVD mortality compared to the chlorthalidone and usual-care groups, respectively. PMID: 28987246 [PubMed - in process]
Source: Journal of the National Medical Association - October 11, 2017 Category: General Medicine Tags: J Natl Med Assoc Source Type: research

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20  years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014
ConclusionGradual implementation of new and established evidence-based treatments in STEMI patients during the last 20  years has been associated with prolonged survival and lower risk of recurrent ischaemic events, although a plateauing is seen since around 2008.
Source: European Heart Journal - August 29, 2017 Category: Cardiology Source Type: research

Long-term risk and predictors of cardiovascular death in stable coronary artery disease: the CORONOR study
Conclusion: In stable CAD patients widely treated by secondary prevention medications, the main causes of CVD are death from HF and sudden death. The risk of CVD can be predicted by simple baseline variables. New therapeutic strategies are needed for the high-risk patients.
Source: Coronary Artery Disease - November 2, 2017 Category: Cardiology Tags: Original Research Source Type: research

Implications of prescribing a fixed-dose combination in clinical cardiology practice: a retrospective observational study using a single medical centre database in Korea
Conclusions FDC discontinuation was common among patients attending the cardiology outpatient clinic. Our analyses suggest that FDC discontinuation in patients at high ASCVD risk may have an impact on CV event rates.
Source: Heart Asia - June 26, 2017 Category: Cardiology Authors: Kim, H., Yoon, H.-J., Park, H.-S., Cho, Y.-K., Nam, C.-W., Han, S., Hur, S.-H., Kim, Y.-N., Kim, K.-B. Tags: Original research Source Type: research

Adhering to the principles of clinical pharmacology - The Correct Fixed Combinations of Antihypertensive Drugs.
Abstract Introduction Hypertension is one of the primary modifiable risk factors for cardiac and renal diseases. The prevalence of hypertension appears to be around 30-45% of the general population, with a steep increase with ageing. The administration of blood pressure-lowering drugs is to reduce the risk of major clinical cardiovascular outcomes: stroke, myocardial infarction, heart failure and cardiovascular deaths. Hypertension guidelines recommend combination therapy in patients with high cardiovascular risk and with subclinical organ damage as well as when monotherapy fails. Areas covered As the etiology of ...
Source: Pharmacological Reviews - December 1, 2017 Category: Drugs & Pharmacology Authors: Paulina L, Elzbieta M, Anna TK, Banach M, Jolanta M Tags: Expert Rev Clin Pharmacol Source Type: research

Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013
CONCLUSIONSAmong CS and NCP with AMI in Ontario, similar improvements in mortality and receipt of treatments were observed between 1995 and 2013. However, compared with NCP, CS had a higher risk of mortality and heart failure. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Inna Y. Gong, Andrew T. Yan, Dennis T. Ko, Craig C. Earle, Winson Y. Cheung, Stuart Peacock, Marlous Hall, Chris P. Gale, Kelvin K. W. Chan Tags: Original Article Source Type: research